Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

Invest in Stem Cells

The human body is home to roughly 200 different cell types. Red blood cells, white blood cells, nerve cells, and bone cells, to name a few, each have their own specific function within our biological ecosystem.

First discovered in human cord blood in 1978, stem cells are undifferentiated cells (serve no specific function) that can be divided into specialized cells (serve a specific function) like skin cells, blood cells, muscle cells, etc. Two types of stem cells exist: multipotent stem cells and pluripotent stem cells. Multipotent stem cells are stem cells that can only turn into cells specific to their tissue (liver stem cells can regenerate liver tissue and muscle stem cells can regenerate muscle fiber but not vice versa). Examples of multipotent stem cells are adult cells and cord blood cells. Pluripotent stem cells are stem cells that can turn into any type of specialized cell (considered the “master builder” cell, they can be turned into nerve cells, muscles cells, blood cells, etc. It is this reason why pluripotent cells are more ideal). Examples of pluripotent stem cells are embryonic cells and iPSC’s or induced pluripotent stem cells.

When specialized cells become damaged due to disease(s), stem cells can be utilized to replenish the damaged cell type. It is this ability that has led stem cells to become a hot topic in the field of regenerative medicine (the process of replacing/reengineering human cells, tissues, and organs).

Stem Cell Research

Stem cell research took the world by storm when the first cloned mammal, Dolly the sheep, made media headlines in 1996. The success of stem cells in the cloning process caused a firestorm of investment into the industry, however, the hysteria was short-lived due to polarizing views and regulation on the technology. This regulation came into play because (at the time) the only way to create a pluripotent cell (a cell that can become any cell in the human body) was to extract them from an embryo and put the embryo in a petri dish. The fact of destroying an embryo, even if only five days old, didn’t mull over well with Bush’s pro-life administration and as such the stem cell industry was hit with regulation. However, a major milestone in the stem cell industry occurred in 2006 when scientist Shinya Yamanaka created the induced pluripotent stem cell or iPS cells. iPS cells are adult stem cells that behave like embryonic stem cells. This was considered a breakthrough because adult stem cells would be genetically reprogrammed to take on the characteristics of embryonic stem cells, completely eliminating the need for an embryo.

iPS cells have reshaped the landscape as biopharmaceutical companies have been leveraging the technology to create an array of cell types. Companies in the field of immunotherapy have been transforming these stem cells into natural killer cells (NK’s) and T cells and companies in the field of regenerative medicine have been utilizing them for applications such as skin and wound healing.

Major Developments

  • In March of 2017, Dr. Masayo Takahashi led a team of scientists to successfully treat the first person, a woman in her eighties suffering from progressive blindness, with iPS stem cells. The cells were injected into the woman’s eyes and although not completely restoring her vision, have proved successful in stabilizing and stopping any further deterioration to her eyesight.
  • Cord-blood banking, which is harvesting the blood of the umbilical cord which contains stem cells, is a rising market globally. The rationale is to have your own stem cells reserve for use when you’re an adult in the advent of being diagnosed with specific disease(s)
  • Recently, scientists in Japan have successfully restored functioning brain cells in monkeys with the use of stem cells. There are hopes that the method can finally be implemented in those suffering from Parkinson’s disease

The Future

There is an investment graveyard full of stem cell companies that were once promising but since have crashed and burned into bankruptcy. A combination of regulation and controversy derailed the potential of the technology for the duration of the 2000’s. Since then, there has been monumental strides made in this exciting field. Statista predicts the stem cell market to reach a valuation of $15 billion by the year 2025.

Combining the fields of gene therapy, CAR T cell therapy, and other forms of regenerative medicine, the stem cell industry will be one to watch over the next decade albeit with much caution.

Stem Cell Stocks

Industry: Biotechnology

Sector: Healthcare

Website: http://www.bluebirdbio.com

Description: bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of -thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Market cap$1.97B
P/E ratio
Earnings per share$ -9.95
Return on equity-46.87%
Profit margin-246.75%
Total revenue$250.73M
Debt / Equity14.25
Price / Book1.44
52 week high$72.51
52 week low$24.24
Shares outstanding$67.14M
Previous close$30.02
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.cellbiomedgroup.com

Description: Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company’s CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.

Fundamentals
Market cap$384.69M
P/E ratio
Earnings per share$
Return on equity0.00%
Profit margin0.00%
Total revenue$0.00
Debt / Equity
Price / Book
52 week high$19.76
52 week low$11.48
Shares outstanding$0.00
Previous close$19.75
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.athersys.com

Description: Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Fundamentals
Market cap$400.55M
P/E ratio
Earnings per share$ -0.42
Return on equity-288.34%
Profit margin0.00%
Total revenue$1.44M
Debt / Equity2.16
Price / Book12.01
52 week high$3.59
52 week low$1.53
Shares outstanding$215.24M
Previous close$1.83
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.caladrius.com

Description: Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Fundamentals
Market cap$102.83M
P/E ratio
Earnings per share$ -0.53
Return on equity-30.84%
Profit margin0.00%
Total revenue$0.00
Debt / Equity1.94
Price / Book1.03
52 week high$4.89
52 week low$1.25
Shares outstanding$59.50M
Previous close$1.74
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.pluristem.com

Description: Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA’s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant’s patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Fundamentals
Market cap$149.45M
P/E ratio
Earnings per share$ -1.58
Return on equity-128.59%
Profit margin0.00%
Total revenue$0.00
Debt / Equity3.14
Price / Book2.98
52 week high$13.29
52 week low$4.30
Shares outstanding$31.53M
Previous close$4.89
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.geron.com

Description: Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Fundamentals
Market cap$484.17M
P/E ratio
Earnings per share$ -0.28
Return on equity-43.70%
Profit margin0.00%
Total revenue$253.00K
Debt / Equity14.09
Price / Book2.24
52 week high$2.40
52 week low$1.04
Shares outstanding$318.53M
Previous close$1.52
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.brainstorm-cell.com

Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer’s disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Fundamentals
Market cap$129.67M
P/E ratio
Earnings per share$ -1.07
Return on equity-273.75%
Profit margin0.00%
Total revenue$0.00
Debt / Equity20.35
Price / Book3.60
52 week high$17.95
52 week low$3.10
Shares outstanding$35.72M
Previous close$3.58
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://vcel.com

Description: Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Fundamentals
Market cap$2.74B
P/E ratio989.00
Earnings per share$0.06
Return on equity2.34%
Profit margin2.31%
Total revenue$124.18M
Debt / Equity39.70
Price / Book20.25
52 week high$60.49
52 week low$10.35
Shares outstanding$46.09M
Previous close$55.47
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.sangamo.com

Description: Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients’ lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company’s zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Fundamentals
Market cap$1.60B
P/E ratio
Earnings per share$ -0.90
Return on equity-26.04%
Profit margin-102.37%
Total revenue$118.19M
Debt / Equity8.46
Price / Book3.17
52 week high$19.43
52 week low$6.97
Shares outstanding$143.25M
Previous close$11.24
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.capricor.com

Description: Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.

Fundamentals
Market cap$100.63M
P/E ratio
Earnings per share$ -0.88
Return on equity-77.95%
Profit margin0.00%
Total revenue$310.25K
Debt / Equity1.52
Price / Book3.22
52 week high$12.32
52 week low$1.30
Shares outstanding$22.80M
Previous close$4.37
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.vistagen.com

Description: VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Fundamentals
Market cap$304.06M
P/E ratio
Earnings per share$ -0.26
Return on equity-30.49%
Profit margin0.00%
Total revenue$647.60K
Debt / Equity3.91
Price / Book3.13
52 week high$3.18
52 week low$0.35
Shares outstanding$143.76M
Previous close$2.09
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.autolus.com

Description: Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.

Fundamentals
Market cap$406.47M
P/E ratio
Earnings per share$ -1.40
Return on equity-29.62%
Profit margin0.00%
Total revenue$1.08M
Debt / Equity
Price / Book0.98
52 week high$17.19
52 week low$5.10
Shares outstanding$70.51M
Previous close$5.77
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.agexinc.com

Description: AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company’s lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington’s disease and other neurological disorders; a collaboration with Sernova Corp.; and a research collaboration with The Ohio State University using AgeX’s brown adipocyte tissue cell therapy candidate AgeX-BAT1 in mice to determine whether transplantation of AgeX-BAT1 cells may improve diet-induced obesity, metabolic health, and cardiac function. The company was founded in 2017 and is based in Alameda, California.

Fundamentals
Market cap$63.35M
P/E ratio
Earnings per share$ -0.29
Return on equity0.00%
Profit margin0.00%
Total revenue$1.87M
Debt / Equity
Price / Book
52 week high$3.93
52 week low$0.67
Shares outstanding$37.94M
Previous close$1.62
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Industry: Biotechnology

Sector: Healthcare

Website: http://www.plustherapeutics.com

Description: Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx’s glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Fundamentals
Market cap$20.84M
P/E ratio
Earnings per share$ -30.62
Return on equity-393.27%
Profit margin0.00%
Total revenue$303.00K
Debt / Equity230.82
Price / Book40.36
52 week high$5.42
52 week low$1.40
Shares outstanding$9.22M
Previous close$2.25
Dividend Analysis
Dividend yield0.00%
Payout ratio0.00%
Trailing Annual Dividend Rate$
Five Year Avg Dividend Yield0.00%
Ex-Dividend date0

Load More

Contact Us For Opportunities in the Private Market